The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis

Arthritis and Rheumatism

Volumn 62, Issue 1, 2010, Pages 280-290

  Reich, Nicole ^a   Maurer, Britta ^b   Akhmetshina, Alfiya ^a   Venalis, Paulius ^a   Dees, Clara ^a   Zerr, Pawel ^a   Palumbo, Katrin ^a   Zwerina, Jochen ^a   Nevskaya, Tatiana ^c   Gay, Steffen ^b   Distler, Oliver ^b   Schett, Georg ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DNA; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NEUTRALIZING ANTIBODY; PLATELET DERIVED GROWTH FACTOR; SCLEROPROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FRA 2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DERMIS; DNA BINDING; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MEDIATOR; MOLECULAR MECHANICS; MOLECULAR THERAPY; MOUSE; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; TRANSGENIC MOUSE; UPREGULATION; VASCULAR DISEASE; WILD TYPE;

ANIMALS; CELLS, CULTURED; DERMIS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOS-RELATED ANTIGEN-2; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLATELET-DERIVED GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 74849137794     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.25056     Document Type: Article

References (38)

1. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428-40.
2. Scheja A, Hellmer G, Wollheim FA, Akesson A. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease. Br J Rheumatol 1993;32: 59-62.
3. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-6.
4. Varga J, Bashey RI. Regulation of connective tissue synthesis in systemic sclerosis. Int Rev Immunol 1995;12:187-99.
5. Gay S, Jones RE Jr, Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989; 92:301-3.
6. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001;20:2401-12.
7. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005;208:126-40.
8. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis. Nat Med 2006;12: 99-106.
9. Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V, et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci U S A 2008;105:10525-30.
10. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
11. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
12. Huber LC, Distler JH, Moritz F, Hemmatazad H, Hauser T, Michel BA, et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 2007;56:2755-64.
13. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008;22:2214-22.
14. Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008;58: 1475-84.
15. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60:219-24.
16. Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J, et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 2008;58:2553-64.
17. Distler JH, Jungel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006;54:214-25.
18. Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005;52: 856-64.
19. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991;19:2499.
20. Distler JH, Jungel A, Huber LC, Seemayer CA, Reich CF 3rd, Gay RE, et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci U S A 2005;102:2892-7.
21. Distler JH, Hagen C, Hirth A, Muller-Ladner U, Lorenz HM, del Rosso A, et al. Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-κB and simian virus 40 promoter factor 1 pathways. Mol Pharmacol 2004;65:389-99.
22. Distler JH, Jungel A, Kurowska-Stolarska M, Michel BA, Gay RE, Gay S, et al. Nucleofection: a new, highly efficient transfection method for primary human keratinocytes*. Exp Dermatol 2005; 14:315-20.
23. 2 via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. Arthritis Rheum 2007;56:3564-74.
24. Kasturi KN, Shibata S, Muryoi T, Bona CA. Tight-skin mouse an experimental model for scleroderma. Int Rev Immunol 1994;11: 253-71.
25. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112:456-62.
26. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
27. Distler JH, Distler O. Imatinib as a novel therapeutic approach for fibrotic disorders. Rheumatology (Oxford) 2009;48:2-4.
28. Huang C, Ma WY, Young MR, Colburn N, Dong Z. Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Natl Acad Sci U S A 1998;95:156-61.
29. Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pennie WD, et al. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 1998;17:3493-8.
30. Young MR, Nair R, Bucheimer N, Tulsian P, Brown N, Chapp C, et al. Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently. Mol Cell Biol 2002;22:587-98.
31. Grigoriadis AE, Schellander K, Wang ZQ, Wagner EF. Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol 1993;122:685-701.
32. Jochum W, David JP, Elliott C, Wutz A, Plenk H Jr, Matsuo K, et al. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 2000;6:980-4.
33. Meixner A, Karreth F, Kenner L, Wagner EF. JunD regulates lymphocyte proliferation and T helper cell cytokine expression. EMBO J 2004;23:1325-35.
34. Schorpp M, Jager R, Schellander K, Schenkel J, Wagner EF, Weiher H, et al. The human ubiquitin C promoter directs high ubiquitous expression of transgenes in mice. Nucleic Acids Res 1996;24:1787-8.
35. Hall MC, Young DA, Waters JG, Rowan AD, Chantry A, Edwards DR, et al. The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-β 1. J Biol Chem 2003; 278:10304-13.
36. Monje P, Marinissen MJ, Gutkind JS. Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor. Mol Cell Biol 2003;23:7030-43.
37. Robledo RF, Buder-Hoffmann SA, Cummins AB, Walsh ES, Taatjes DJ, Mossman BT. Increased phosphorylated extracellular signal-regulated kinase immunoreactivity associated with proliferative and morphologic lung alterations after chrysotile asbestos inhalation in mice. Am J Pathol 2000;156:1307-16.
38. Chung KY, Agarwal A, Uitto J, Mauviel A. An AP-1 binding sequence is essential for regulation of the human α2(I) collagen (COL1A2) promoter activity by transforming growth factor-β. J Biol Chem 1996;271:3272-8.